Marijuana via joint

Phase 1Small molecule

Marijuana via joint is one of 2 small molecule programs targeting Cigarette Smoking-Related Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cigarette Smoking-Related CarcinomaNot yet recruiting

Cigarette Smoking-Related CarcinomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Cigarette Smoking-Related Carcinoma

#DrugCompanyPhaseTrials

Ilaris

Novartis

Phase 2

1 2

Marijuana via joint

RRoswell Park Cancer Institute

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Not yet recruiting

Cigarette Smoking-Related Carcinoma

NCT06055231

Clinical

Trials by Indication[1]

Cigarette Smoking-Related Carcinoma1 trial

A Randomized Within-Subject Cross-Over Study to Compare Short-Term PK/PD Effects of Vaping THC-containing Liquids vs. Smoked Cannabis

Not yet recruiting·RRoswell Park Cancer Institute·Phase 1·NCT06055231·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Marijuana via joint. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Marijuana via joint compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Marijuana via joint. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roswell Park Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRoswell Park Cancer Institute

Marijuana via joint

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Cigarette Smoking-Related Carcinoma1 trial

References

Drug Info

Quick Facts

Related News